Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Capital Expenditures (2023 - 2025)

Historic Capital Expenditures for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $10000.0.

  • Inhibrx Biosciences' Capital Expenditures fell 9595.14% to $10000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $47000.0, marking a year-over-year decrease of 9921.97%. This contributed to the annual value of $2.6 million for FY2024, which is 4345.74% down from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Capital Expenditures is $10000.0, which was down 9595.14% from $21000.0 recorded in Q1 2025.
  • Over the past 5 years, Inhibrx Biosciences' Capital Expenditures peaked at $3.4 million during Q4 2023, and registered a low of $10000.0 during Q3 2025.
  • Over the past 3 years, Inhibrx Biosciences' median Capital Expenditures value was $408000.0 (recorded in 2023), while the average stood at $829875.0.
  • Within the past 5 years, the most significant YoY rise in Inhibrx Biosciences' Capital Expenditures was 5659.05% (2024), while the steepest drop was 9953.52% (2024).
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Capital Expenditures stood at $3.4 million in 2023, then plummeted by 99.54% to $16000.0 in 2024, then tumbled by 37.5% to $10000.0 in 2025.
  • Its Capital Expenditures was $10000.0 in Q3 2025, compared to $21000.0 in Q1 2025 and $16000.0 in Q4 2024.